Journal article
Sodium-glucose co-transporter-2 inhibitor cardiovascular outcome trials and generalizability to English primary care
- Abstract:
-
Aim
Expand abstract
To identify people in English primary care with equivalent cardiovascular risk to participants in the sodium–glucose co‐transporter‐2 inhibitor (SGLT‐2i) cardiovascular outcome trials (CVOTs). A secondary objective was to report the usage of SGLT‐2is.
Methods
Cross‐sectional analysis of people registered with participating practices in the Royal College of General Practitioners (RCGP) Research and Surveillance Centre (RSC) network on the 31 December 2016. We derived: (1) ...
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Authors
Funding
AstraZeneca UK Limited
More from this funder
Bibliographic Details
- Publisher:
- Wiley Publisher's website
- Journal:
- Diabetic Medicine Journal website
- Volume:
- 37
- Issue:
- 9
- Pages:
- 1499-1508
- Place of publication:
- England
- Publication date:
- 2020-03-28
- Acceptance date:
- 2020-02-28
- DOI:
- EISSN:
-
1464-5491
- ISSN:
-
0742-3071
- Pmid:
-
32128875
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
1093052
- Local pid:
- pubs:1093052
- Deposit date:
- 2020-08-15
Terms of use
- Copyright holder:
- Hinton et al.
- Copyright date:
- 2020
- Rights statement:
- ©2020 The Authors. Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial‐NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record